- Home
- EDF vs LRMR Comparison
EDF vs LRMR Comparison
Compare EDF & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- LRMR
- Stock Information
- Founded
- EDF 2010
- LRMR N/A
- Country
- EDF United States
- LRMR United States
- Employees
- EDF N/A
- LRMR N/A
- Industry
- EDF Investment Managers
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- LRMR Health Care
- Exchange
- EDF Nasdaq
- LRMR Nasdaq
- Market Cap
- EDF 148.8M
- LRMR 171.6M
- IPO Year
- EDF N/A
- LRMR N/A
- Fundamental
- Price
- EDF $4.97
- LRMR $2.67
- Analyst Decision
- EDF
- LRMR Strong Buy
- Analyst Count
- EDF 0
- LRMR 7
- Target Price
- EDF N/A
- LRMR $18.86
- AVG Volume (30 Days)
- EDF 160.6K
- LRMR 1.2M
- Earning Date
- EDF 01-01-0001
- LRMR 08-06-2025
- Dividend Yield
- EDF 13.14%
- LRMR N/A
- EPS Growth
- EDF N/A
- LRMR N/A
- EPS
- EDF N/A
- LRMR N/A
- Revenue
- EDF N/A
- LRMR N/A
- Revenue This Year
- EDF N/A
- LRMR N/A
- Revenue Next Year
- EDF N/A
- LRMR N/A
- P/E Ratio
- EDF N/A
- LRMR N/A
- Revenue Growth
- EDF N/A
- LRMR N/A
- 52 Week Low
- EDF $3.51
- LRMR $1.61
- 52 Week High
- EDF $5.50
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- EDF 50.98
- LRMR 56.20
- Support Level
- EDF $4.96
- LRMR $2.60
- Resistance Level
- EDF $5.05
- LRMR $3.02
- Average True Range (ATR)
- EDF 0.07
- LRMR 0.25
- MACD
- EDF -0.01
- LRMR 0.01
- Stochastic Oscillator
- EDF 33.00
- LRMR 51.35
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.